The charts on this page feature a breakdown of the total annual pay for the top executives at G1 THERAPEUTICS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. G1 THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. G1 THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Rajesh K. Malik M.D.
Chief Medical Officer
Total Cash $587,673 Equity $905,657 Other $8,700 Total Compensation $1,502,030
Jennifer K. Moses
Chief Financial Officer
Total Cash $597,568 Equity $905,736 Other $8,700 Total Compensation $1,512,004
Mark Avagliano
Chief Business Officer
Total Cash $597,352 Equity $905,657 Other $8,700 Total Compensation $1,511,709
John E. Bailey Jr.
Chief Executive Officer and President
Total Cash $1,029,000 Equity $7,668,055 Other $8,700 Total Compensation $8,705,755
Andrew Perry
Chief Commercial Officer
Total Cash $302,175 Equity $2,824,285 Other $750 Total Compensation $3,127,210
For its 2021 fiscal year, G1 THERAPEUTICS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
John E. Bailey Jr. CEO Pay $8,705,755 Median Employee Pay $198,441 CEO Pay Ratio 44:1
For its 2021 fiscal year, G1 THERAPEUTICS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Alicia Secor Total Cash $791,854
Cynthia L. Flowers Total Cash $448,297
Fredric N. Eshelman, Pharm.D. Total Cash $15,385
Garry A. Nicholson Total Cash $465,385
Glenn P. Muir Total Cash $458,297
Mark Velleca, M.D., Ph.D. Total Cash $242,692
Seth A. Rudnick, M.D. Total Cash $456,291
Willie A. Deese Total Cash $434,017

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.